CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 35 target
Drug / intervention
Concurrent chemotherapy +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04275687
NCT04275687Phase 2Unknown
CompareCT.gov

Thoracic Re-irradiation For Locoregionally Recurrent Non-small Cell Lung Cancer Using Hypofractionated Technique.

Sun Yat-sen University·interventional·Posted Feb 19, 2020·Updated Feb 21, 2020

In Brief

A Phase 2 clinical trial evaluating thoracic irradiation and Concurrent chemotherapy for Loco-regionally Recurrent NSCLC After Thoracic Radiotherapy. Targeting 35 participants across 1 site.

Detailed Summary

This prospective phase II study is to assess the efficacy and safety of thoracic re-irradiation for locoregionally recurrent non-small cell lung cancer using hypofractionated technique.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLoco-regionally Recurrent NSCLC After Thoracic Radiotherapy
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
2020202120222023202420252026
First PostedFeb 19, 2020
Enrollment StartMar 1, 2020
Primary CompletionFeb 1, 2025
TodayJul 1, 2026
Enrollment to primary: 4.9 yearsPosted 6.4 years ago

Interventions

thoracic irradiationradiation

For peripherally located recurrent tumors, stereotactic body radiation therapy is used at 5000-6000 cGy in 10 fractions. For centrally located recurrent tumors, adaptive hypofractionated radiation is used: Patients are irradiated at 3000-4000cGy in 6-10 daily fractions in the first course. After a four-week interval, patients who have non-progressive disease and an adequate pulmonary function undergo adaptive re-planning, and are irradiated at 2400-3500cGy in 4\~7 daily fractions as a boost.

Concurrent chemotherapydrug

For centrally located recurrent tumors, concurrent chemotherapy consists of weekly docetaxel and nedaplatin.